Εμφάνιση απλής εγγραφής

dc.creatorPapadimitriou D., Antonelou R., Miligkos M., Maniati M., Papagiannakis N., Bostantjopoulou S., Leonardos A., Koros C., Simitsi A., Papageorgiou S.G., Kapaki E., Alcalay R.N., Papadimitriou A., Athanassiadou A., Stamelou M., Stefanis L.en
dc.date.accessioned2023-01-31T09:42:17Z
dc.date.available2023-01-31T09:42:17Z
dc.date.issued2016
dc.identifier10.1002/mds.26615
dc.identifier.issn08853185
dc.identifier.urihttp://hdl.handle.net/11615/77574
dc.description.abstractBackground: G209A SNCA mutation carriers represent an important group of genetic PD. We describe motor and nonmotor features of G209A SNCA mutation carriers. Methods: Longitudinal clinical assessments over 2 years were collected in 22 symptomatic and 8 asymptomatic G209A SNCA mutation carriers. Motor and nonmotor rating scales were administered. Correlations were performed between clinical variables and disease duration or age. Penetrance was calculated using Kaplan-Meier survival curves. Results: Asymptomatic carriers did not manifest clear premotor symptoms, but symptomatic carriers often reported that olfactory dysfunction and rapid eye movement sleep behavior disorder preceded motor symptoms. Prominent motor decline and deterioration of autonomic and cognitive function occurred at follow-up; such nonmotor features correlated with disease duration, but not age. Disease penetrance was estimated at around 90%. Conclusions: This study may help to inform clinical trials and provide the basis for studies of disease modifiers in genetic synucleinopathy cohorts. © 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Societyen
dc.language.isoenen
dc.sourceMovement Disordersen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84963811810&doi=10.1002%2fmds.26615&partnerID=40&md5=88724c7a1b21bfcfef39d6e956bca3ad
dc.subjectalpha synucleinen
dc.subjectalpha synucleinen
dc.subjectSNCA protein, humanen
dc.subjectadulten
dc.subjectage distributionen
dc.subjectageden
dc.subjectArticleen
dc.subjectautonomic dysfunctionen
dc.subjectclinical articleen
dc.subjectclinical assessmenten
dc.subjectclinical featureen
dc.subjectcohort analysisen
dc.subjectcontrolled studyen
dc.subjectcorrelational studyen
dc.subjectdementiaen
dc.subjectdepressionen
dc.subjectdisease durationen
dc.subjectfemaleen
dc.subjectfollow upen
dc.subjectgene mutationen
dc.subjectgenetic risken
dc.subjectheterozygoteen
dc.subjecthumanen
dc.subjectlongitudinal studyen
dc.subjectmaleen
dc.subjectmental deteriorationen
dc.subjectonset ageen
dc.subjectparasomniaen
dc.subjectParkinson diseaseen
dc.subjectpenetranceen
dc.subjectphenotypic variationen
dc.subjectpriority journalen
dc.subjectprospective studyen
dc.subjectrating scaleen
dc.subjectsex differenceen
dc.subjectsleep disorderen
dc.subjectsmelling disorderen
dc.subjectUnified Parkinson Disease Rating Scaleen
dc.subjectvery elderlyen
dc.subjectautonomic neuropathyen
dc.subjectcomplicationen
dc.subjectdementiaen
dc.subjectgeneticsen
dc.subjectheterozygoteen
dc.subjectmiddle ageden
dc.subjectmutationen
dc.subjectParkinson diseaseen
dc.subjectpathophysiologyen
dc.subjectpenetranceen
dc.subjectpsychosisen
dc.subjectsmelling disorderen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectalpha-Synucleinen
dc.subjectAutonomic Nervous System Diseasesen
dc.subjectDementiaen
dc.subjectFemaleen
dc.subjectHeterozygoteen
dc.subjectHumansen
dc.subjectLongitudinal Studiesen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMutationen
dc.subjectOlfaction Disordersen
dc.subjectParkinson Diseaseen
dc.subjectPenetranceen
dc.subjectPsychotic Disordersen
dc.subjectJohn Wiley and Sons Inc.en
dc.titleMotor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Studyen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής